Shares of Sino Biopharmaceutical Ltd. (HKG:1177), a leading biopharmaceutical company in China, surged by 7.25% on October 4, 2024, closing at a high of HK$4.15 per share.
The rally in Sino Biopharm's stock price came on the heels of news that its subsidiary, Chia Tai Tianqing Pharmaceutical, had been actively purchasing shares of the company under a share award scheme. According to a filing with the Hong Kong Stock Exchange, Chia Tai Tianqing acquired 187,385,000 shares of Sino Biopharm from May 7 to September 30, 2024, for a total consideration of HK$550.6 million.
The share buyback program, which is aimed at rewarding employees and aligning their interests with those of shareholders, is seen as a vote of confidence in Sino Biopharm's future prospects. By repurchasing its own shares, the company reduces the number of outstanding shares, effectively increasing the ownership stake of existing shareholders and potentially boosting earnings per share.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。